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Epidermal growth factor receptor
Endocytosis
Late endosomes
MAP kinase signalingEndocytosis of activated growth factor receptors regulates spatio-temporal cellular signaling. In the case of
the EGF receptor, sorting into multivesicular bodies (MVBs) controls signal termination and subsequently
leads to receptor degradation in lysosomes. Annexin A1, a Ca2+-regulated membrane binding protein often
deregulated in human cancers, interacts with the EGF receptor and is phosphorylated by internalized EGF
receptor on endosomes. Most relevant for EGF receptor signal termination, annexin A1 is required for the
formation of internal vesicles in MVBs that sequester ligand-bound EGF receptor away from the limiting
membrane. To elucidate the mechanism underlying annexin A1-dependent EGF receptor trafﬁcking we
employed an N-terminally truncated annexin A1 mutant that lacks the EGF receptor phosphorylation site
and the site for interaction with its protein ligand S100A11. Overexpression of this dominant-negative mutant
induces a delay in EGF-induced EGF receptor transport to the LAMP1-positive late endosomal/lysosomal
compartment and impairs ligand-induced EGF receptor degradation. Consistent with these ﬁndings, EGF-
stimulated EGF receptor and MAP kinase pathway signaling is prolonged. Importantly, depletion of S100A11
also results in a delayed EGF receptor transport and prolonged MAP kinase signaling comparable to the trafﬁck-
ing defect observed in cells expressing the N-terminally truncated annexin A1 mutant. These results strongly
suggest that the function of annexin A1 as a regulator of EGF receptor trafﬁcking, degradation and signaling is
critically mediated through an N-terminal interaction with S100A11 in the endosomal compartment. This inter-
action appears to be essential for lysosomal targeting of the EGF receptor, possibly by providing a physical
scaffold supporting inward vesiculation in MVBs. This article is part of a Special Issue entitled: 12th European
Symposium on Calcium.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Growth factor receptor activation triggers a complex network of
signaling events that requires accurate tempo-spatial regulation. To
avoid constitutive signaling, endocytosis and lysosomal targeting termi-
nates cellular signaling of activated cell surface receptors. In many cases
ligand-induced activation of the surface receptor induces endocytosis.
Ligand-bound receptors are transported to early endosomes where they
are sorted either for recycling to the plasmamembrane or for degradation
in the lysosomal compartment [1,2]. An importantmechanismduring the
transport along the endocytic pathway is the sorting of activated signaling
receptors into multivesicular endosomes [3]. Through budding ofopean Symposium on Calcium.
emistry, Centre for Molecular
march-Str. 56, 48149 Münster,
er).
l rights reserved.vesicles into the endosomal lumen, receptors are sequestered into
these intraluminal vesicles and thereby efﬁciently sorted away from
molecules destined for recycling. In the case of activated epidermal
growth factor (EGF) receptor (EGFR) this sorting into multivesicular
endosomes is essential for signal termination [4]. Several cellular com-
ponents including the endocytic adaptors Eps15, Hrs and the ESCRT
machinery of proteins have been described to participate in the sorting
of activated and internalized EGFR. Furthermore, several members of
the annexin protein family, including annexins (Anx) A1, A2, A6 and,
as we showed recently, AnxA8 have been implicated in EGFR signal ter-
mination and lysosomal degradation [5–8]. This involves a speciﬁc role
for AnxA1, which affects EGF-stimulated inward vesiculation of EGFR
containing membrane domains during the formation of intraluminal
vesicles in multivesicular bodies (MVBs) [9]. However, although inter-
nalization of activated receptors into intraluminal vesicles is a critical
mechanism linking degradation and signal termination, the complex
molecular mechanisms underlying this process remain to be fully
characterized.
1701M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711The EGFR belongs to the ErbB family of receptor tyrosine kinases and
is a central player in cellular signaling events that control awide range of
processes [10]. Identiﬁcation of activated EGFR on endosomes that is
associated with various downstream effectors led to the concept of
“signaling endosomes” [11]. Recent studies not only suggest that
endosomal trafﬁcking is important for exploiting the full biological
activity of EGFR, but also reveal that EGFR-mediated signaling controls
the endocytic pathway itself [12]. Targeting EGFR to internal vesicles
of nascent multivesicular endosomes is mediated by ubiquitination of
the cytoplasmic receptor domain [13]. Recognition of the ubiquitinated
receptor by the Endosomal Sorting Complex Required for Transport
(ESCRT) component Hrs (Hepatocyte growth factor Regulated tyro-
sine kinase Substrate) ultimately leads to receptor concentration into
clathrin-coated regions [14]. While sequential interactions of ESCRT-I, -II
and -III with ubiquitinated receptors have been intensively studied, the
mechanisms concentrating receptors at sites of vesicle formation and
mediating vesicle budding at these sites are not yet fully understood
[4]. Annexin A1 has been implicated in linking these concentrated
receptors to the inward vesiculation process [15]. It is a member of
the annexin family of Ca2+-regulated membrane binding proteins
that participate in different membrane-related events including mem-
brane organization and vesicular trafﬁcking, some of those related to
the regulation of EGFR signaling and trafﬁcking [5–8,16]. AnxA1 ex-
pression is deregulated in various cancers and in this context has been
linked to signal transduction, tumor invasion and cellular differentia-
tion and proliferation [17,18]. Interestingly, AnxA1 is down-regulated
in breast cancer [19], whereas up-regulation of the EGFR is often associ-
ated with breast cancer progression [20].
Structurally, AnxA1 is composed of the highly conserved annexin
core domain that mediates Ca2+-dependent phospholipid binding
and a unique N-terminal domain that modulates the membrane bind-
ing speciﬁcity of the core domain [21] and harbors sites for posttransla-
tional modiﬁcation, most notably a tyrosine at position 21 that is
phosphorylated by internalized EGFR [22,23]. In membrane-bound
AnxA1 the N-terminal domain faces the cytoplasm and is available for
speciﬁc protein–protein interactions. The best characterized ligand of
this N-terminal domain is the EF-hand-type Ca2+-binding protein
S100A11 which itself forms a dimer and can thereby bridge two
membrane-bound AnxA1 moieties [24–26]. Furthermore, the AnxA1
binding partner S100A11 has recently been demonstrated to represent
a novel diagnostic marker for breast carcinoma [27]. Together with the
reported role of AnxA1 inmediating the EGF-stimulated inward vesicu-
lation in MVBs [9] these expression studies suggest a function of the
protein and possibly the AnxA1/S100A11 complex in tumorigenesis of
breast cancer [28].
Despite association of S100A11 with AnxA1 on early endosomes
[29], it is not known if AnxA1/S100A11 interaction is involved in the
regulation of EGFR trafﬁcking along the endocytic pathway. In this
study we demonstrate that binding of S100A11 to the N-terminal do-
main of AnxA1 is crucially involved in regulating lysosomal degradation
of the EGFR. Both depletion of S100A11 and overexpression of an
N-terminal AnxA1 deletion mutant lacking the S100A11 binding site
resulted in delayed transport of internalized EGF along the endocytic
pathway which impaired lysosomal degradation of the EGFR. Thus,
modulation of AnxA1 by EGFR phosphorylation and S100A11 binding
are important events in regulating the lysosomal degradation of the
EGFR.
2. Materials and methods
2.1. Cell culture, transfection and antibodies
HeLa and A431 cells (both expressing endogenous AnxA1, data
not shown) were maintained in Dulbecco's modiﬁed Eagle's medium
High Glucose (PAA) supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 7%CO2 and 37 °C. Cells grown on coverslips were transiently transfected
with Lipofectamine 2000 (Invitrogen) according to the manufacturer's
protocol and further cultivated for 24 hours. Expression constructs
of AnxA1full-length–GFP and AnxA1core–GFP have been described
previously [21]. For siRNA-mediated S100A11 gene silencing, the
S100A11-speciﬁc SMARTpool reagent (Dharmacon) consisting of four
S100A11-targeting siRNAs was used. AllStars negative control siRNA
(Qiagen) was used as a non-silencing control. For transfection of HeLa
cellswith siRNAwe employed oligofectamine (Invitrogen) and cultivat-
ed the transfected cells for 72 hours.
Mouse monoclonal antibodies against human lysosome-associated
membrane protein 1 (LAMP1) were obtained from the Developmental
Studies Hybridoma Bank (clone H4A3; University of Iowa, Iowa City,
Iowa, USA). Rabbit polyclonal anti-human S100A11 antibodies were
obtained from Proteintech Europe, rabbit polyclonal anti-EGFR anti-
bodies and rabbit polyclonal anti-Rab5 antibodies from Santa Cruz Bio-
technology, mouse monoclonal anti-β-actin antibody from Sigma, and
mouse monoclonal anti-GFP antibody from Invitrogen. Mouse monoclo-
nal anti-phospho-tyrosine (P-Tyr-100) antibodies, mouse monoclonal
anti-phospho-MEK1/2 antibodies, rabbit polyclonal anti-MEK1/2 anti-
bodies, mouse monoclonal anti-phosphoERK1/2 antibodies and rabbit
polyclonal anti-ERK1/2 antibodies were purchased from Cell Signaling
Technology.
2.2. EGF and transferring uptake
Serum-starved cells were incubated with either 2 μg/ml Texas
Red-coupled EGF (Invitrogen) for 10 min or with 50 μg/ml Texas-Red
conjugated transferrin (Invitrogen) for 5 or 30 min in serum-free culture
medium. After washing with serum-free medium cells were either ﬁxed
immediately or further cultivated for 15 or 30 min. All incubation steps
were conducted at 37 °C.
2.3. Immunocytochemistry and confocal ﬂuorescence microscopy
HeLa cells grown on coverslips were ﬁxed with 4% paraformalde-
hyde (PFA) containing 0.2% Triton X-100 for 3 min and subsequent
incubation with 4% PFA for 10 min. Cells were blocked with 2% bovine
serum albumin (BSA) in PBS followed by incubation with the primary
antibody for 45 min at room temperature. After intensive washing
with PBS, cells were incubated with the respective secondary antibody
conjugated with Cy5. An LSM 510 META microscope (Carl Zeiss) with
a Plan-Apochromat 63×/1.4 oil immersion objective was used for con-
focal microscopy.
2.4. Colocalization of EGF with LAMP1
For colocalization analysis images of a confocal plane in the lower
part of 20 transfected cells were acquired for each condition. The
amount of colocalization was calculated using BioImageXD [30] and
statistical signiﬁcance of the results from four independent experiments
was evaluated by paired Student's t test. P≤0.05 indicated a signiﬁcant
difference.
2.5. Analysis of EGFR degradation and activation
Serum-starved HeLa and A431 cells were incubated with EGF (A431:
10 ng/ml, HeLa: 100 ng/ml, Biomol Research Laboratories) and 10 μg/ml
cycloheximide for 15, 30 or 60 min. After stimulation, cells were scraped
in ice-cold PBS and pelleted. Cell pellets were resuspended in 8 M urea
and sonicated. Equal protein amounts were analyzed by SDS-PAGE
followed by immunoblotting with actin serving as an internal loading
control. Quantiﬁcation of signal intensities was carried out by densito-
metric analysis using the ImageJ software (National Institutes of Health,
Bethesda, Maryland, USA). Statistical signiﬁcance of results obtained
from at least three independent experiments was evaluated using the
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activation of EGFR and the MAP kinase pathway, cell lysates were sepa-
rated by SDS PAGE and immunoblotswere analyzed using the appropri-
ate antibodies for activated EGFR, MEK1/2 and ERK1/2, respectively.2.6. Subcellular fractionation by sucrose step gradient
Fractions of early and late endosomeswere obtained by ﬂotation in a
sucrose step gradient as described previously [31] and protein concen-
trations in the fractions were measured with the Bradford assay. Equal
amounts of protein were immunoblotted for the presence of AnxA1–
GFP, AnxA1core–GFP and Rab5 using the appropriate antibodies. Rab5
served as a marker for the quality of early endosomal enrichment. For
each gradient, the ratios of the late endosomal/early endosomal GFP
signal intensities were calculated. Data were collected from three inde-
pendent transfections and the statistical signiﬁcance was evaluated by
paired Student's t test.Fig. 1. Transport of EGF to the late endosomal compartment is retarded in HeLa cells ex
N-terminally truncated mutant AnxA1core–GFP were serum-starved and allowed to intern
EGF positive endosomes were more dispersed in cells expressing AnxA1core–GFP. (C) The c
from confocal images of cells expressing either full-length or truncated AnxA1–GFP that h
expression construct and time point, 20 cells were evaluated and the results are expressed
t-test was employed for analysis of statistical signiﬁcance (*P≤0.05). Lower panel: repre
time point, signiﬁcantly less colocalization of EGF with the late endosomal/lysosomal mark
distribution of the endosomes. For a better visualization of the colocalization, the origina
sections. Bars, 10 μm.2.7. AnxA1/S100A11 interaction using surface plasmon resonance (SPR)
Recombinant human S100A11 expressed and puriﬁed as described
previously [25] was dialysed against HBS-P for SPR interaction analysis
and protein concentration was determined using the Bradford assay.
SPR experimentswere carried out on a Biacore 3000 instrument (GE
Healthcare). HBS-P (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.005% v/v
Tween 20) ﬁltered through 0.22 μM ﬁlters (Millipore) and degassed
was used as running buffer. Puriﬁed bovine AnxA1 (BioDesign Int)
was immobilized via the amine coupling method on a carboxy-methyl
dextran CM5 chip at a ﬂow rate of 5 μl/min following the manufac-
turer's instructions. Brieﬂy, a blank surface of a CM5 chip was activat-
ed with a 7 min injection of a 1:1 mixture of 0.2 M 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 0.05 M
N-hydroxysuccinimide (NHS) and approximately 900 response units
(RU) of AnxA1 in 10 mM acetate buffer, pH 5.0, were immobilized by
injection of protein solution (30 μg/ml). The surface was deactivated
via a subsequent 7 min injection of 1.0 M ethanolamine, pH 8.5, topressing the AnxA1 core domain. (A) Cells expressing GFP, full-length AnxA1 or the
alize Texas Red-coupled EGF for 10 min. (B) Upon an additional 15 min chase period,
olocalization of the late endosomal/lysosomal marker LAMP1 with EGF was quantiﬁed
ad been subjected to a 10 min EGF pulse, followed by 15 or 30 min of chase. For each
as the mean percentages±SEM from four independent experiments. Paired Student's
sentative confocal sections of cells after a chase period of 15 min are shown. At this
er LAMP1 was observed in AnxA1core–GFP expressing cells. Note the more peripheral
l LAMP1 signals are converted to green. All images shown represent single confocal
1704 M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711block free ester groups. As reference a ﬂow cell was activated via EDC/
NHS anddeactivatedwith ethanolamine but no proteinwas immobilized.
During measurements the response in this ﬂow cell was subtracted from
responses in all other ﬂow cells. For interaction analysis, different concen-
trations of puriﬁed S100A11 diluted in HBS-P containing 1 mM Ca2+
were injected for 3 min following a dissociation time of 6 min at a ﬂow
rate of 40 μl/min. HBS-P containing 1 mMCa2+wasused as runningbuff-
er and sensorgrams (response units versus time) were recorded at 25 °C.
A 10 μl pulse injection of 10 mM EDTAwas used to wash away dissociat-
ed S100A11 and to regenerate the surface. Experiments were repeated
three times with double injections. The response at equilibrium reso-
nance (Req) of a series of S100A11 injections was plotted against itsFig. 2. AnxA1 distribution on endosomes. (A) HeLa cells expressing AnxA1–GFP or AnxA1co
ically label both the early and recycling endosomes. Note that the distribution of these
transfected with AnxA1–GFP or AnxA1core–GFP were separated by ﬂotation on a sucrose s
protein in the late (LE) or early (EE) endosomal fraction. The early endosomal marker Rab5
densitometrically quantiﬁed and the enrichment on early endosomes was calculated as ratio
a statistically signiﬁcant difference (P≤0.05) as revealed by paired t test.concentrations (M) and theKD valuewas calculated via the BIAEvaluation
Software 4.1 (Biacore AB).
2.8. Migration assay
For cell migration assays, 1×106 HeLa cells transiently expressing
AnxA1–GFP or AnxA1core–GFP were seeded into cylinders placed in a
48-well plate. Cells were allowed to attach for 2 hours at 7% CO2 and
37 °C in serum-depleted medium with or without the addition of
100 ng/ml EGF. After removal of the cylinders the cells were rinsed and
the respective medium was added. Three wells were used for each
condition. The area covered by the cells was recorded directly after there–GFP were allowed to internalize Texas Red-coupled transferrin for 30 min to specif-
transferrin receptor enriched compartments appears similar. (B) Endosomes of cells
tep gradient and analyzed by immunoblotting for the presence of the respective fusion
served as a control for efﬁcient endosome enrichment. GFP signals in the fractions were
LE/EE. Mean values±SEM from three independent experiments are shown. * indicates
1705M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711removal of the cylinder and 24 hours later. The cell-covered areas (% of
the total area) from four independent experiments were quantiﬁed by
ImageJ software. The statistical signiﬁcance was evaluated by paired
Student's t-test with P≤0.05 indicating a signiﬁcant difference.2.9. Clonogenic assay
A431 cells expressing either AnxA1–GFP or AnxA1core–GFP were
seeded in 6-well plates (5×103 cells/well) and grown in DMEM, 1%
FCS with or without 10 ng/ml EGF for 1–2 weeks. Cells were then
ﬁxed and stained with DIFF-QUIK Staining Set (Siemens). Colonies
containing more than 40 cells were quantiﬁed using ImageJ software.
Data were collected from four independent experiments and theFig. 3. EGFR transport and signal termination is impaired in cells expressing the AnxA1 co
stimulated with EGF for either (A) 5 min or (B) 30 min and then immunostained with an
appeared more dispersed in cells expressing AnxA1core–GFP upon 30 min of EGF stimulation
with 100 ng/ml EGF in the presence of cycloheximide for the indicated periods of time
antibodies. A representative immunoblot from ﬁve independent experiments is shown. In ad
products are detected. Actin was used as a control to ensure equal loading of total cellular pro
mature EGFR, and expressed as the percentage of the EGFR level of cells at 0 min. Data re
(D) Serum-starved A431 cells left untreated (control) or expressing either AnxA1–GFP or
MAP kinases MEK1/2 and their corresponding activation states were assessed by immunobstatistical signiﬁcance was evaluated by repeated measures one-way
ANOVA followed by Tukey's multiple comparison test. P≤0.05 indicat-
ed a signiﬁcant difference.3. Results
3.1. N-terminally truncated AnxA1 delays EGF transport and lysosomal
degradation
The annexin A1 N-terminal domain contains two important sites for
posttranslational modiﬁcation, tyrosine 21 that is phosphorylated by
internalized EGFR [22,23], and the S100A11 binding site consisting of
residues 1–12. Phosphorylation at tyrosine 21 is discussed to triggerre domain. Serum-starved HeLa cells expressing AnxA1–GFP or AnxA1core–GFP were
ti-EGFR antibodies to visualize EGFR distribution. Note that EGFR positive endosomes
. (C) Serum-starved HeLa cells expressing AnxA1–GFP or AnxA1core–GFP were treated
. Degradation of EGFR was analyzed by immunoblotting cell lysates with anti-EGFR
dition to the 180 kDa band corresponding to mature EGFR, intermediate EGFR cleavage
teins. Kinetics of EGFR degradation was assessed by densitometric quantiﬁcation of the
present mean values±SEM. * indicates a statistically signiﬁcant difference (P≤0.05).
AnxA1core–GFP were treated with 10 ng/ml EGF for 30 min. Levels of EGFR and the
lotting the cell lysates with the respective antibodies. A representative blot is shown.
Fig. 3 (continued).
1706 M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711A1 N-terminal cleavage, thereby generating an annexin A1 core that
cannot interact with S100A11 and has been discussed to participate in
the MVB inward vesiculation process [5]. However, the exact cleavage
site is not known. Therefore, we used an N-terminal deletion mutant
which encompasses all possible cleavage products to study the potential
involvement of the AnxA1/S100A11 complex in EGFR internalization.Fig. 4. Interaction of AnxA1 with S100A11. (A) HeLa cells expressing AnxA1–GFP were im
confocal section is shown. Boxed inserts show high magniﬁcation views of selected cell re
vitro utilizing Surface Plasmon Resonance. Puriﬁed S100A11 (0.03125–1 μM) was passed
were plotted against time. Steady state afﬁnity was calculated using the response at equil
revealed a KD value of ~1.5×10−7.HeLa cells were transfected with AnxA1full-length–GFP or AnxA1core–
GFP and the internalization and endocytic trafﬁcking of ﬂuorescently
labeled EGF was followed using a pulse-chase regime. Texas Red-conju-
gated EGF was ﬁrst allowed to internalize into transfected HeLa cells
for 10 min. In control cells expressing GFP or AnxA1full-length–GFP a
general cytosolic distribution of EGF-containing vesicles was detectable.munostained for the localization of endogenous S100A11. A representative image of a
gions. Bar, 10 μm. (B) The afﬁnity for S100A11 binding to AnxA1 was determined in
over immobilized AnxA1 in the presence of 1 mM Ca2+ and the response units (RU)
ibrium (Req) at the end of injection as function of the sample concentration (M) and
1707M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711EGF-containing vesicles in cells expressing the N-terminally truncated
mutant appearedmore peripherally enriched (Fig. 1A), possibly reﬂecting
a delay in transport. After an additional incubation for 15 min, EGF-
containing vesicles already clustered in the perinuclear region in cells ex-
pressing full-length AnxA1 and in GFP-expressing control cells. InFig. 5. S100A11 depletion results in impaired EGF transport and sustained EGF-induced sig
siRNA (lower panel) were serum-starved overnight. Texas Red-coupled EGF was internaliz
Images represent single confocal sections. Individual outlines of S100A11-depleted cells ar
selected cell regions. Bars, 10 μm. (B) Total levels of the MAP kinases ERK1/2 and S100A1
were detected with anti-ERK and anti-S100A11 antibodies, respectively. (C) Cells transfected
night and then treated with 100 ng/ml EGF for the indicated times. ERK1/2 levels and activcontrast, labeled EGF was found in dispersed vesicular structures in the
AnxA1core–GFP expressing cells (Fig. 1B). A similar delay in EGF-
transport to the perinuclear region could be observed in A431 squamous
carcinoma cells expressing the AnxA1 core mutant (our unpublished
data).naling. (A) HeLa cells transfected with either control siRNA (upper panel) or S100A11
ed for 10 min, followed by a 15 min chase period. Fixed cells were stained for LAMP1.
e indicated with dashed white lines. Boxed inserts show high magniﬁcation views of
1 in the lysates from cells transfected with control siRNA or S100A11-speciﬁc siRNA
for 48 hours with control siRNA or S100A11-speciﬁc siRNA were serum-starved over-
ation proﬁle was assessed by Western blot analysis.
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1709M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711To identify if the dispersed distribution of EGF-containing vesicles in
N-terminal AnxA1 core mutant expressing cells would correlate with
reduced amounts of EGF that can reach the lysosomal compartment,
we analyzed the degree of colocalization of internalized labeled EGF
with LAMP1, a marker for the late endosomal/lysosomal compartment
in AnxA1–GFP cells and cells expressing AnxA1core–GFP. No difference
in the amount of EGF colocalizingwith lysosomeswas observed between
cells expressing full-length AnxA1 and AnxA1core–GFP expressing cells
after the initial stimulation of 10 min. However, when internalized EGF
was chased for 15 min a substantial amount of EGF could be found
in LAMP1-positive endosomes in cells expressing full-length AnxA1,
whereas inAnxA1core–GFP expressing cells this amountwas signiﬁcant-
ly reduced, indicating a transitory delay in earlier endocytic transport
steps along the degradative pathway (Fig. 1C). Although colocalization
of LAMP1 and EGF was similar in cells expressing full length or the
AnxA1core–GFP mutant after a chase period of 30 min, these ﬁndings
suggested a delayed transport of EGF to the LAMP1-positive compart-
ment upon overexpression of the N-terminal AnxA1 mutant.
To further validate these ﬁndings, we hypothesized that a different
pathway emerging from the early endosomes, the recycling pathway
back to theplasmamembrane,which is typically takenby the transferring
receptor, should not be affected. Therefore, AnxA1–GFP and AnxA1core–
GFP expressing cells were continuously incubated with ﬂuorescently
labeled transferrin for 30 min. At this time all TfR-positive vesicles repre-
sent either early or recycling endosomes. As shown in Fig. 2A, no alter-
ations in the distribution of the endosomal pool containing labeled
transferrin could be observed between AnxA1–GFP and Anx1core–GFP
expressing cells.
We previously demonstrated that endogenous and ectopically
expressed full length AnxA1 localized on early endosomal membranes,
while the AnxA1 core mutant lacking the N-terminal domain was asso-
ciated with late endosomal structures. The difference in the target
membrane preferences is not affected by the GFP tag [21,32]. To address
if the delayed transport of EGF toward the late endosomal compartment
in AnxA1core–GFP expressing cells would be associatedwith a different
location ofwild type andmutant AnxA1,we compared their localization
utilizing subcellular fractionation on sucrose gradients. Early and late
endosomal fractions were isolated by their different ﬂotation behavior
[31] and consistent with published data, the early endosomal marker
Rab5 co-puriﬁed with early endosomes (EE) and was only faintly
observed in the late endosomal (LE) fractions (Fig. 2B). To assess
the enrichment, equal protein amounts of the corresponding EE and
LE fractions were immunoblotted using anti-GFP antibodies and the
LE/EE ratios were calculated from the densitometric analysis of the re-
spective AnxA1 fusion protein. In contrast to AnxA1–GFP, AnxA1core–
GFP was found signiﬁcantly enriched in the late endosomal fraction.
This is consistent with previous ﬁndings that the N-terminal part of
AnxA1 is essential for directing the protein preferentially to early
endosomes.
3.2. Delayed EGFR trafﬁcking is linked to prolonged EGFR signaling
To identify if the delay in EGF transport in AnxA1core–GFP express-
ing cells was associatedwith impaired trafﬁcking of the EGFR, HeLa cells
expressing either AnxA1–GFP or AnxA1core–GFP were serum-starved
over night and then stimulated with EGF for 5 or 30 min. Whereas
EGFR localization in wild type and mutant AnxA1 expressing cells was
comparable upon 5 min EGF incubation (Fig. 3A), indirect immunoﬂuo-
rescence utilizing anti-EGFR antibodies revealed that after 30 min ofFig. 6. AnxA1core expression enhances migratory potential and clonogenic growth. (A) Cell m
GFP in the presence or absence (w/o) of EGF (100 ng/ml). After 24 hours, the cell-covered ar
mean values±SEM from at least four independent experiments. Statistical analysis was p
grown with EGF at indicated time points. (B) Clonogenic survival of A431 cells expressing A
control cells, cells expressing AnxA1–GFP and AnxA1core–GFP expressing cells. After 5 days
performed using ANOVA followed by Tukey's multiple comparison test. *P≤0.05. The uppeEGF treatment, the EGFR-positive compartment appeared more
dispersed in the AnxA1core–GFP expressing cells (Fig. 3B), further
supporting the view that transport along the endosomal pathway
is affected in AnxA1core-expressing cells.
Depletion of AnxA1 has been shown to impair EGF-induced
inward vesiculation in MVBs [9]. Since such impairment should af-
fect the degradation of internalized EGFR, we investigated a possible
role of the N-terminal domain of AnxA1 in the ligand-induced degrada-
tion of EGFR. HeLa cells transfected with either AnxA1full-length–GFP
or AnxA1core–GFP were serum-starved to promote EGFR accumula-
tion at the plasmamembrane and then stimulated for 0–60 min with
EGF in the presence of cycloheximide in order to inhibit new protein
synthesis. Analysis of EGFR levels in total cell lysates by immuno-
blotting revealed that following 60 min of EGF stimulation the
amount of mature EGFR was signiﬁcantly decreased in control
cells expressing AnxA1full-length–GFP. In contrast, lysates of cells
expressing AnxA1core–GFP still contained a substantial amount of
mature EGFR at 60 min after stimulation (Fig. 3C). Similar results
were obtained for EGF-stimulated degradation of the EGFR in
A431 cells (data not shown). Collectively, impaired EGFR degrada-
tion and delayed EGF-transport in cells expressing the AnxA1 core
mutant suggest that loss of AnxA1/S100A11 interaction could affect
early to late endosomal transport of endocytosed EGFR.
As EGFR degradation is closely coupled to the termination of EGF
signal transduction, we also analyzed the activation of EGFR and the
downstream signaling kinase MEK1/2 in mutant AnxA1 expressing
cells. A431 cells were chosen for these experiments since they express
high levels of EGFR [33]. A431 cells were transfected with AnxA1–GFP
or AnxA1core–GFP, incubated with EGF for 30 min and EGFR tyrosine
phosphorylation and MEK1/2 phosphorylation was determined. At
this time point, substantial amounts of EGFR are already degraded in
EGF-treated A431 cells [34]. Compared to untransfected control or
AnxA1full-length–GFP expressing cells a markedly prolonged EGF-
stimulated activation of the EGFR was observed in cells expressing the
AnxA1 core mutant (Fig. 3D). Consistent with enhanced EGFR tyrosine
phosphorylation, EGF-stimulated activation of MEK1/2 was also
increased in AnxA1core–GFP overexpressing cells (Fig. 3D). Taken
together, these ﬁndings indicate that activated EGFR is not targeted
efﬁciently to late endosomes/lysosomes in AnxA1core–GFP express-
ing cells, thereby causing enhanced and prolonged signaling from
EGFR and downstream effector pathways.
3.3. Depletion of S100A11 impairs transport of EGF
To address if AnxA1/S100A11 interaction could be involved in the
lysosomal targeting of EGFR within endosomal compartments and
possibly MVBs, we ﬁrst aimed to conﬁrm that AnxA1 is able to target
the binding partner S100A11 to early endosomal membranes [29]. In
line with previous observations, endogenous S100A11 clearly
colocalized with full-length AnxA1–GFP in unstimulated HeLa cells
(Fig. 4A). For a further characterization of the binding properties of
AnxA1 and S100A11, we employed SPR to obtain quantitative informa-
tion on the afﬁnity of this interaction. PuriﬁedAnxA1was immobilized on
a CM5 sensor chip, and increasing concentrations of puriﬁed S100A11
were injected in the presence of 1 mM Ca2+. Analysis of the data follow-
ing the steady state afﬁnity model revealed a KD of~1.5×10−7 for the in-
teraction of S100A11 with AnxA1 (Fig. 4B). To provide evidence that
AnxA1/S100A11 complex formation is needed for trafﬁcking of ligand-
activated EGFR, we next analyzed whether S100A11 has a role in EGFigration assays were performedwith HeLa cells expressing AnxA1–GFP or AnxA1core–
ea in each well was calculated as percentage of the total well area. The graph shows the
erformed using Student's t-test. *P≤0.05. Upper panel: Representative results of cells
nxA1–GFP or AnxA1core–GFP. Clonogenic assays were performed with untransfected
, numbers of colonies consisting of ≥40 cells were determined. Statistical analysis was
r panel shows a representative result of four independent experiments.
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internalized into serum-starved HeLa cells depleted for S100A11 and
control siRNA transfected cells for 10 min incubation followedby an addi-
tional 15 min chase.While clustering of EGF-containing endosomal struc-
tures could be observed in control siRNA transfected cells (Fig. 5A, upper
panel), EGF-containing vesicles were more dispersed in cells deplet-
ed of S100A11 (Fig. 5A, lower panel, compare enlarged areas in
Fig. 5A). These results indicate that S100A11 is indeed important
for EGF transport along the degradative pathway. We reasoned that
if S100A11 acted together with AnxA1 on EGFR trafﬁcking, the de-
layed transport of EGF should give rise to enhanced activation of
the MAPKinase signaling cascade, similar to the ﬁndings observed
in AnxA1core-expressing cells (see Fig. 3D). We ﬁrst conﬁrmed by
immunoblotting that treatment of cells with the target-speciﬁc
siRNA almost eliminated S100A11 expression, but had no impact
on ERK1/2 expression (Fig. 5B). Next, the effect of S100A11 knock
down on EGF-stimulated ERK activation was determined byWestern
blotting for phosphorylated ERK1/2. As shown in Fig. 5C, suppression
of S100A11 expression prolonged the ERK activation proﬁle, further
supporting a model that S100A11, through its interaction with
AnxA1, regulates the endosomal trafﬁcking of EGFR.
3.4. AnxA1core expression affects EGF-induced cell migration and cell
growth
To investigate if prolonged EGFR activation and MAP kinase signal-
ing upon disturbing AnxA1/S100 complex formation were of any phys-
iological signiﬁcance and possibly relevant in the development or
progression of cancer, we ﬁrst investigated the migration behaviour of
HeLa cells expressing either AnxA1–GFP or AnxA1core–GFP. Indeed,
cells that had been transfected with the AnxA1–GFP construct could
not migrate as efﬁciently as cells expressing AnxA1core–GFP (Fig. 6A).
This difference was most robustly observed 24 hours after initiation of
the migration.
We next employed the clonogenic assay as a tool to test whether
AnxA1core–GFP-induced prolonged EGF-activated MAP kinase signal-
ing had any effects on the survival and proliferation of cells. Upon plat-
ing, A431 cells were maintained for 10 days in EGF containing media
and the obtained clones were then stained and counted. Whereas ex-
pression of AnxA1–GFP did not change the number of clones compared
to cells expressing GFP only, more clones derived from AnxA1core-
expressing cells were determined (Fig. 6B). Statistical analysis revealed
that expression of AnxA1core was indeed associated with a signiﬁcant
increase in clone numbers.
4. Discussion
Stimulation of cells with EGF results in clustering of the receptor
tyrosine kinase EGFR with its bound ligand and subsequent internaliza-
tion into endocytic vesicles [35]. Activated and signaling competent
EGFR is then sorted into early endosomes, sequestered into intraluminal
vesicles of MVBs and ultimately degraded in the lysosomal compart-
ment. Tight spatio-temporal regulation of the multitude of transport
steps is essential for accurate termination of EGF signaling. Here we
demonstrate the requirement of the N-terminal domain of AnxA1 in
transport steps that result in the sequestration of internalized EGFR
into the internal vesicles of MVBs. Thus, AnxA1 could function in the
silencing of activated EGFR and hence in the regulation of mitogenic
signals that also play a role in certain tumor developments. EGFR is
implicated in a major fraction of human cancers and deregulation of
AnxA1 expression has been reported in numerous cancer types [18].
Especially in breast cancer progression, down-regulation of AnxA1
[19] seems to correlate with up-regulation of the EGFR and its down-
stream effector pathways [20]. As AnxA1 is required for efﬁcient EGFR
degradation, down-regulation of AnxA1 in tumorigenesis may contrib-
ute to tumor pathology by potentiating EGF signaling.Previous reports suggested that loss or depletion of AnxA1 did not
signiﬁcantly alter EGF degradation and only caused a small delay in
EGFR degradation [9]. In the present study the employment of an
N-terminally truncated AnxA1 mutant resulted in a signiﬁcant delay
in EGFR degradation. These differing results may be reconciled by the
ﬁnding that the AnxA1 core protein redistributes from early to late
endosomes when compared to the full-length AnxA1 protein [32,36].
Whereas depletion or loss of AnxA1may result in compensatory mech-
anismpossibly involving other annexin familymembers, the ectopically
expressed AnxA1 core mutant might act in a dominant-negative manner
andefﬁciently and speciﬁcally competewith endogenousAnxA1 for bind-
ing to late endosomes. In line with a reported role of AnxA1 in inward
vesiculation in multivesicular endosomes [9], the speciﬁc replacement
of endogenous AnxA1by the coremutantmaypreclude functional redun-
dancy within the annexin family and therefore delay EGFR transport and
degradation more severely than the total lack of AnxA1.
As AnxA1 is present on internal vesicles ofMVBs after EGF-stimulation
[9] and associates with the EGFR via its core domain [36], we conclude
that the AnxA1 core domain directly interacts with the EGFR during
EGFR-transport along the endocytic pathway. The EGFR kinase phosphor-
ylates AnxA1 on the tyrosine residue at position 21 [37–40] and this
phosphorylation in turn has been demonstrated to be essential for
EGF-stimulated AnxA1-dependent inward vesiculation in MVBs [9].
The delay in lysosomal EGFR degradation observed here upon ex-
pression of the AnxA1 core mutant correlates with the reported effects
of N-terminal AnxA1 phosphorylation on both inward vesiculation and
proteolytic degradation of AnxA1 and internalized EGFR. In line with
these observations, an AnxA1 mutant deﬁcient in the N-terminal
phosphorylation site is not able to compensate for the effect of AnxA1
depletion on EGF-stimulated MVB biogenesis [9]. While such a phos-
phorylation deﬁcient mutant is still able to exert functions that are me-
diated through interactionwith itsN-terminal binding partner S100A11
[25], the AnxA1 coremutant employed in this study also interfereswith
functions of a putative AnxA1-S100A1 complex. In this study, we could
show that both ablation of S100A11 and overexpression of the AnxA1
core mutant delayed trafﬁcking and degradation of the EGFR and inter-
fered with termination of EGF-activated signaling, indicating that
not only AnxA1 membrane binding but also complex formation with
S100A11 is essential for EGF transport along the degradative pathway.
As AnxA1 could exhibitmembrane aggregating properties by formation
of a heterotetrameric complexwith S100A11 [41], such a complex could
function in membrane fusion events during inward vesiculation along
the degradative pathway. Based on our observations it is conceivable
that the heterotetrameric complex of AnxA1 and S100A11 forms on
the perimeter endosomal membrane during initial membrane invagi-
nation in nascent MVBs, thereby stabilizing membrane interactions at
sites of emerging inward vesicles, for example by linking opposing
membranes at the invaginating inward bud. Expression of an AnxA1
mutant lacking the N-terminal domain most likely results in the efﬁ-
cient replacement of endogenous AnxA1 during the passage of EGFR
from early to late endosomes, thereby most likely inhibiting the postu-
lated mechanism that couples AnxA1 to inward vesiculation in MVBs.
4.1. Concluding remarks
Endocytic transport of ligand-bound EGFR and receptor silencing by
internal vesicle sequestration and ultimate degradation is a key event in
regulating the duration of the downstream MAP kinase signaling cas-
cade. We show that expression of the AnxA1 core mutant prolongs
this signaling, supporting the view that the AnxA1/S100A11 complex
participates in EGFR inward vesiculation and thereby the termination
of EGF signaling. This directly couples the AnxA1/S100A11 complex to
the spatio-temporal regulation of EGFR signal transduction. Upon
activation, EGFR family members signal through MEK to ERK and cell
migration and proliferation are among the processes regulated through
activation of the ERK signaling cascade. Our observations that expression
1711M. Poeter et al. / Biochimica et Biophysica Acta 1833 (2013) 1700–1711of the AnxA1core mutant increased cell migration and enhanced the
ability to form colonies from single cells emphasize the importance
of the AnxA1/S100A11 complex formation to successfully balance
EGF signaling. Since inappropriate signaling through EGFR/Ras/Raf/
MAPK pathway is found in many tumors [42] these mechanistic insights
may provide the molecular basis for the postulated involvement of
S100A11 and AnxA1 in tumorigenesis.
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